SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001013762-23-001374
Filing Date
2023-10-04
Accepted
2023-10-04 07:32:21
Documents
15
Period of Report
2023-10-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea186309-8k_bioplusacq.htm   iXBRL 8-K 41922
2 TERMINATION AND RELEASE AGREEMENT, DATED OCTOBER 4, 2023, BY AND AMONG BIOPLUS A ea186309ex10-1_bioplusacq.htm EX-10.1 40401
3 PRESS RELEASE DATED OCTOBER 4, 2023 ea186309ex99-1_bioplusacq.htm EX-99.1 9700
  Complete submission text file 0001013762-23-001374.txt   334423

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bios-20231004.xsd EX-101.SCH 4143
5 XBRL DEFINITION FILE bios-20231004_def.xml EX-101.DEF 27248
6 XBRL LABEL FILE bios-20231004_lab.xml EX-101.LAB 37766
7 XBRL PRESENTATION FILE bios-20231004_pre.xml EX-101.PRE 25868
9 EXTRACTED XBRL INSTANCE DOCUMENT ea186309-8k_bioplusacq_htm.xml XML 6760
Mailing Address 260 MADISON AVENUE, SUITE 800 NEW YORK NY 10016
Business Address 260 MADISON AVENUE, SUITE 800 NEW YORK NY 10016 2122874092
BioPlus Acquisition Corp. (Filer) CIK: 0001856653 (see all company filings)

IRS No.: 981583272 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41116 | Film No.: 231306576
SIC: 3845 Electromedical & Electrotherapeutic Apparatus